Valganciclovir: an advance in cytomegalovirus therapeutics. - Wikidata - wikimedia - TriplyDB

Valganciclovir: an advance in cytomegalovirus therapeutics.

Valganciclovir: an advance in cytomegalovirus therapeutics.

http://www.wikidata.org/entity/Q34648667

about

The use of antiviral drugs during the neonatal period Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens.Cytomegalovirus retinitis in Good syndrome: case report and review of literature Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection.Pharmacokinetic considerations in the use of antivirals in neonates.Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells.Resistance of human cytomegalovirus to cyclopropavir maps to a base pair deletion in the open reading frame of UL97.Neurotoxicity related to valganciclovir in a child with impaired renal function: usefulness of therapeutic drug monitoring.

P2860

Q35789702-53B76047-BC6A-4301-8A1C-BEE87601B3DF Q36473125-6DCB7A68-DB33-4882-AC8A-034C7F227535 Q37892349-3574D96C-94D3-4FD7-AAE7-2D63F7F342CC Q38215682-1767E32D-1C01-4363-800C-C6E5DFE7AD6A Q38271850-D114E312-9E48-4A3F-85DE-FFA30C822207 Q38624965-4C9606E7-9DB2-4C07-B9C9-F5367154427D Q39025231-87B96DD0-B8B8-4D58-A53B-60B7E6497A83 Q42286758-D0FA57AB-F1E4-49FF-A417-7C089FB4AC59 Q46861990-1CE97A4E-AEAA-4095-82F4-D3BF4C61D054

P2860

Valganciclovir: an advance in cytomegalovirus therapeutics.

http://www.wikidata.org/entity/Q34648667

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Valganciclovir: an advance in cytomegalovirus therapeutics.

@ast

Valganciclovir: an advance in cytomegalovirus therapeutics.

@en

Valganciclovir: an advance in cytomegalovirus therapeutics.

@nl

type

label

Valganciclovir: an advance in cytomegalovirus therapeutics.

@ast

Valganciclovir: an advance in cytomegalovirus therapeutics.

@en

Valganciclovir: an advance in cytomegalovirus therapeutics.

@nl

prefLabel

Valganciclovir: an advance in cytomegalovirus therapeutics.

@ast

Valganciclovir: an advance in cytomegalovirus therapeutics.

@en

Valganciclovir: an advance in cytomegalovirus therapeutics.

@nl

P1433

Q34648667-117DD59B-4D7E-4EC4-BFC1-E29BBB0225FC

P1476

Q34648667-A0EBA936-A0C1-4CE5-A4DA-15D4D52AF98E

P2093

Q34648667-50462315-83E8-43DA-B05E-FD4DF9362A00

Q34648667-61483AB6-0014-4543-8F66-BE143D9D70DC

P2860

Q34648667-34D9B172-45E4-4E2D-A4B9-052E556E385B

Q34648667-4B07ECF4-1441-42D8-B48A-BF024BAE3DAC

Q34648667-8549D98C-5094-400E-BC71-F984C0DF25EE

Q34648667-91BCEFDF-CC4F-4B3D-83CE-D79DB1394AA6

Q34648667-B0D56907-62A5-4281-A340-1D9E3E7634B8

Q34648667-D74EA2E5-A639-43E8-B996-B8D690DE69F2

Q34648667-F7AD7FDD-B821-43F2-813B-52F0BECB41DD

Q34648667-F7D8FEB5-05D6-4648-AA0E-E09BBF3E35E4

P304

Q34648667-CE629EC4-73E0-4A61-83D6-F87CB41F8347

P31

Q34648667-0d089111-4d6c-4fbe-9f39-49cab329f5e2

Q34648667-BDDCF1E2-4022-4146-B992-897EAB673E8A

P356

Q34648667-51451488-2975-4EBE-8524-ECA38BC6760C

P407

Q34648667-0D028A2E-0481-4559-AA87-D16E0082F724

P433

Q34648667-8F78F5F1-A742-4B7B-AB05-1AB6E1C9FDD0

P478

Q34648667-355B42B9-54BB-4839-AD6A-C59F6D10A2ED

P577

Q34648667-3FBEADF3-3E31-45EB-93D5-78C5BA1DC71D

P698

Q34648667-63A85344-B954-4829-9D51-08751429645A

P921

Q34648667-6D4B1FF7-B295-486A-8C1D-DF5623E06422

P356

P1433

Annals of Pharmacotherapy

P1476

Valganciclovir: an advance in cytomegalovirus therapeutics.

@en

P2093

Ian R McNicholl

http://www.w3.org/2001/XMLSchema#string

Jennifer M Cocohoba

http://www.w3.org/2001/XMLSchema#string

P2860

Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects.

Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2.

Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA.

Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis.

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy.

Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.

P304

1075-1079

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1A393

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2002-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12022911

http://www.w3.org/2001/XMLSchema#string

P921

Cytomegalovirus